

Filippo Pietrantonio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6477687/publications.pdf>

Version: 2024-02-01

205
papers

7,854
citations

53794

45
h-index

71685

76
g-index

209
all docs

209
docs citations

209
times ranked

10333
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	6.3	27
2	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	6.4	15
3	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	2.8	13
4	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	3.7	3
5	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
6	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	1.6	52
7	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	1.6	9
8	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	3.0	2
9	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	4.4	10
10	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 167, 23-31.	2.8	8
11	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
12	Negative Ultraslection of Patients With <i>RAS</i> / <i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2200037.	3.0	11
13	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	9.4	48
14	<i>MGMT</i> inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	4.6	2
15	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	6.4	6
16	Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. <i>International Journal of Cancer</i> , 2022, 151, 1760-1769.	5.1	6
17	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS</i> / <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	1.6	24
18	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	2.8	14

#	ARTICLE	IF	CITATIONS
19	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	1.1	5
20	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021, 107, 150-159.	1.1	8
21	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 4-10.	1.0	16
22	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 3332-3342.	1.5	19
23	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	3.7	9
24	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	2.8	12
25	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	2.2	4
26	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
27	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	7.0	14
28	Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. <i>ESMO Open</i> , 2021, 6, 100036.	4.5	87
29	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
30	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	3.7	8
31	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	5.3	6
32	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83.	2.8	29
33	Microsatellite instability in Gastric Cancer: Between lights and shadows. <i>Cancer Treatment Reviews</i> , 2021, 95, 102175.	7.7	88
34	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	6.3	12
35	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
36	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	11.2	72

#	ARTICLE	IF	CITATIONS
37	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021, 1, 311-325.	0.2	0
38	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	3.7	31
39	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	2.8	45
40	Author response to Colle et al. , 2021, 9, e003138.		0
41	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	2.3	12
42	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	7.1	80
43	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
44	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	2.8	5
45	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	3.7	6
46	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 82, 101935.	7.7	17
47	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	3.0	6
48	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	2.8	17
49	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	2.8	23
50	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	2.6	53
51	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020, 9, 2019.	4.1	30
52	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	3.7	26
53	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	6.4	93
54	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	2.8	10
56	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020, 19, 219-225.	2.3	45
57	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	10.7	196
58	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 685-698.	2.8	11
59	MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study's Response. <i>Clinical Cancer Research</i> , 2020, 26, 3495-3495.	7.0	1
60	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	2.8	11
61	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	3.7	29
62	Caring for Patients With Cancer During the COVID-19 Outbreak in Italy. <i>JAMA Oncology</i> , 2020, 6, 821.	7.1	30
63	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 783-794.	2.2	7
64	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020, 147, 2303-2315.	5.1	14
65	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.3	20
66	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	2.3	16
67	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	30.7	118
68	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	7.0	22
69	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	11
70	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
71	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	7.1	70
72	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	7.7	60

#	ARTICLE	IF	CITATIONS
73	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	6.4	24
74	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	1.6	65
75	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	1.6	293
76	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	3.3	21
77	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell "Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019, 79, 5884-5896.	0.9	53
78	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	2.0	16
79	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	1.9	26
80	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	3.3	38
81	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	3.3	22
82	Lack of Benefit From Anti-EGFR Treatment in <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.3	7
83	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	2.3	12
84	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	7.0	67
85	Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	4.5	14
86	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	2.6	12
87	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	2.0	35
88	Phase II Study of Tivantinib and Cetuximab in Patients With <i>KRAS</i> Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019, 18, 125-132.e2.	2.3	35
89	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	4.5	3
90	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	4.1	34

#	ARTICLE	IF	CITATIONS
91	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	1
92	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	2.8	9
93	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
94	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	7.1	280
95	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019, 145, 576-585.	5.1	21
96	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 66-66.	1.6	17
97	Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 259-277.	3.1	4
98	Correction to: Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 987-987.	1.5	18
99	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 878-884.	1.5	55
100	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018, 13, 227-234.	3.6	33
101	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	6.4	17
102	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	1.2	72
103	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
104	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389.	4.5	4
105	Glomerular filtration rate: A prognostic marker in atrial fibrillation? A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. <i>Clinical Cardiology</i> , 2018, 41, 1570-1577.	1.8	8
106	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. <i>Cell Metabolism</i> , 2018, 28, 848-865.e6.	16.2	184
107	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	3.7	46
108	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , 2018, 19, 1047-1068.	1.3	12

#	ARTICLE	IF	CITATIONS
109	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	4.5	20
110	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	23
111	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	2.6	17
112	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	1.9	11
113	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	1.2	32
114	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , 2018, 9, 2287.	12.8	18
115	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3505-3505.	1.6	23
116	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017, 17, 331-336.	2.0	10
117	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	183
118	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	2.8	27
119	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	5.3	32
120	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	2.8	54
121	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	2.4	10
122	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206.	2.8	22
123	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017, 28, 3009-3014.	1.2	72
124	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , 2017, 93, 279-286.	1.9	9
125	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	3.7	27
126	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	4.5	10

#	ARTICLE	IF	CITATIONS
127	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	27.8	480
128	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	6.4	31
129	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	2.6	28
130	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	7.0	148
131	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	1.2	43
132	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 167-175.	1.5	41
133	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	2.3	12
134	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 148-163.	1.4	81
135	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	1.8	28
136	Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , 2017, 8, 55353-55360.	1.8	33
137	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845.	3.0	12
138	Perspective: How to Improve Patient Selection in Refractory Metastatic Colorectal Cancer. <i>Tumori</i> , 2016, 102, P1-P2.	1.1	0
139	How the Lab is Changing Our View of Colorectal Cancer. <i>Tumori</i> , 2016, 102, 541-547.	1.1	15
140	Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. <i>Tumori</i> , 2016, 102, e15-e19.	1.1	11
141	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 4222-4230.	1.5	30
142	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 13665.	12.8	170
143	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016, 139, 2859-2864.	5.1	94
144	Toward the molecular dissection of peritoneal pseudomyxoma. <i>Annals of Oncology</i> , 2016, 27, 2097-2103.	1.2	59

#	ARTICLE	IF	CITATIONS
145	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	3.7	94
146	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016, 6, 1315-1333.	9.4	137
147	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 963-971.	9.4	85
148	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	4.4	36
149	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 209-222.	4.4	92
150	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	4.4	11
151	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	3.6	23
152	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 24-28.	4.4	21
153	Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	5.3	37
154	Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 56-62.	0.8	13
155	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015, 10, 127.	2.9	2
156	LightSNIP assay is a good strategy for pharmacogenetics test. <i>Frontiers in Pharmacology</i> , 2015, 6, 114.	3.5	5
157	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 156-166.	4.4	61
158	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	2.5	22
159	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015, 16, 2069-2081.	1.3	14
160	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 587-594.	2.8	425
161	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
162	In Reply. <i>Oncologist</i> , 2015, 20, e5-e5.	3.7	1

#	ARTICLE	IF	CITATIONS
163	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015, 51, 473-481.	2.8	17
164	Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8884-8895.	4.1	13
165	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 272-281.	4.4	15
166	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	1.2	137
167	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	1.2	105
168	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015, 51, 800-807.	2.8	46
169	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	2.4	52
170	BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015, 113, 1634-1635.	6.4	11
171	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	3.7	42
172	Reply to the letter to the editor "New life for retrospective study in the Precision Oncology Era" by Orlandi et al.. <i>Annals of Oncology</i> , 2015, 26, 2353.	1.2	0
173	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.6	28
174	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
175	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. <i>Cancers</i> , 2014, 6, 1753-1768.	3.7	14
176	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
177	TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. <i>Oncology</i> , 2014, 86, 289-294.	1.9	10
178	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , The, 2014, 15, e581.	10.7	1
179	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1228-1237.	2.4	39
180	Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 545-549.	1.3	9

#	ARTICLE	IF	CITATIONS
181	Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2014, 9, e108940.	2.5	55
182	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014, 9, 155-162.	3.6	26
183	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	1.2	67
184	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , 2014, 11, 259-262.	1.5	4
185	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014, 2, 835.	0.8	27
186	MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises. <i>Current Pharmaceutical Design</i> , 2014, 20, 3982-3990.	1.9	38
187	Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. <i>World Journal of Gastroenterology</i> , 2014, 20, 4516.	3.3	30
188	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013, 30, 610.	2.5	7
189	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013, 15, 582-586.	2.4	2
190	Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?. <i>Oncology</i> , 2013, 84, 191-199.	1.9	29
191	Role of cMET in the Development and Progression of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18056-18077.	4.1	47
192	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. <i>Cancer Biology and Therapy</i> , 2013, 14, 1098-1103.	3.4	27
193	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , 2013, 33, 1257-66.	1.1	50
194	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer—subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , 2012, 23, 2771-2772.	1.2	1
195	Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2012, 17, 1426-1428.	3.7	10
196	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemo-naïve Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	3.7	19
197	Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. <i>Medical Oncology</i> , 2012, 29, 2838-2841.	2.5	3
198	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012, 98, 267-9.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Management of advanced genitourinary tumors. Tumori, 2012, 98, 264-6.	1.1	0
200	Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Drugs and Aging, 2011, 28, 83-91.	2.7	2
201	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology, 2011, 6, 181-186.	3.6	7
202	Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report. Tumori, 2010, 96, 154-156.	1.1	10
203	An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review. Tumori, 2010, 96, 1031-1034.	1.1	1
204	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	1.8	3
205	Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study. International Journal of Cancer, 0, , .	5.1	6